Home
Diseases
Metastatic NSCLC

Metastatic NSCLC

Disease

Related News

FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC

Mar 25, 2026

The FDA approved subcutaneous amivantamab for EGFR-mutated NSCLC in December 2025 based on phase 3 PALOMA-3 trial data showing noninferior efficacy with reduced infusion reactions and 5-minute administration time. The formulation decreases infusion-related reactions from 66% to 13% and improves patient convenience and quality of life. Recent MARIPOSA trial updates show amivantamab plus lazertinib extends median overall survival by at least 12 months versus osimertinib monotherapy.

ImmunityBio Resubmits ANKTIVA Bladder Cancer Application to FDA, Advances Saudi Approvals

Mar 09, 2026

ImmunityBio resubmitted its supplemental BLA to the FDA for ANKTIVA in papillary bladder cancer after providing additional data. The company also received encouragement from Saudi regulators to submit a recombinant BCG application and expand ANKTIVA approvals.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07524257	Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC	NOT_YET_RECRUITING	PHASE3
NCT07243132	Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)	RECRUITING
NCT06159790	A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	COMPLETED	PHASE3
NCT05617313	Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer	TERMINATED	PHASE2
NCT05480865	SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation	TERMINATED	PHASE1
NCT05339568	Patient's Whole Process Follow-up Management(HOPE-1)	RECRUITING
NCT05255302	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction	RECRUITING	PHASE2/PHASE3
NCT05091190	Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers	ACTIVE_NOT_RECRUITING	NA
NCT04846452	Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC	UNKNOWN	PHASE2
NCT04615884	Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients	WITHDRAWN	NA